CABA – cabaletta bio, inc. (US:NASDAQ)
Stock Stats
News
First Patients Dosed with Cabaletta Bio's Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform [Yahoo! Finance]
First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform
Cabaletta Bio (CABA) was upgraded by Wall Street Zen from "strong sel
Cabaletta Bio (CABA) had its price target lowered by Morgan Stanley from $14.00 to $13.00. They now have an "overweight" rating on the stock.
Cabaletta Bio (CABA) had its price target raised by Guggenheim from $15.00 to $16.00. They now have a "buy" rating on the stock.
Form PRE 14A Cabaletta Bio, Inc. For: Jun 09
Form S-8 Cabaletta Bio, Inc.
Form 10-K Cabaletta Bio, Inc. For: Dec 31
Form 8-K Cabaletta Bio, Inc. For: Mar 23
Form 4 Cabaletta Bio, Inc. For: Mar 02 Filed by: Gerard Michael
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.